Cargando…

Immunotherapy for Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Kröger, Nicolaus, Mohty, Mohamad, Nagler, Arnon, Yi, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546469/ https://www.ncbi.nlm.nih.gov/pubmed/23346187 http://dx.doi.org/10.1155/2012/797165

Ejemplares similares

Immunobiology and Pharmacologic Manipulation of Dendritic and Regulatory Cells
por: Mohty, Mohamad, et al.
Publicado: (2013)

Looking Ahead: Clinical Hematology International Turns One
por: Mohty, Mohamad, et al.
Publicado: (2020)

Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other
por: Mohty, Mohamad, et al.
Publicado: (2020)

Clinical Hematology International: Why a New Journal in Hematology?
por: Mohty, Mohamad, et al.
Publicado: (2019)

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
por: Danylesko, Ivetta, et al.
Publicado: (2012)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
por: Yousef, Sara, et al.
Publicado: (2015)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Management of patients with multiple myeloma during the COVID-19 pandemic
por: Malard, Florent, et al.
Publicado: (2020)

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
por: Brissot, Eolia, et al.
Publicado: (2019)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
por: Mohty, Razan, et al.
Publicado: (2022)

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT
por: Shimoni, Avichai, et al.
Publicado: (2019)

Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT
por: Munker, Reinhold, et al.
Publicado: (2017)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
por: Mohty, Mohamad, et al.
Publicado: (2020)

The Role of Immunotherapy in Multiple Myeloma
por: Kocoglu, Mehmet, et al.
Publicado: (2016)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

Immunotherapy for the treatment of multiple myeloma
por: Boussi, Leora S., et al.
Publicado: (2022)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2019)

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel
por: Bonifazi, Francesca, et al.
Publicado: (2020)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

P854: EFFECT OF HPSE AND HPSE2 SNPS ON THE RISK OF DEVELOPING PRIMARY PARASKELETAL MULTIPLE MYELOMA
por: Ostrovsky, Olga, et al.
Publicado: (2023)

The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party
por: Rubio, Marie T., et al.
Publicado: (2016)

Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report
por: Passweg, Jakob R, et al.
Publicado: (2018)

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma
por: Ostrovsky, Olga, et al.
Publicado: (2023)

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study
por: Ruggeri, Annalisa, et al.
Publicado: (2016)

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT
por: Santoro, Nicole, et al.
Publicado: (2018)

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
por: Baron, Frédéric, et al.
Publicado: (2019)

Development of Novel Immunotherapies for Multiple Myeloma
por: Al-Hujaily, Ensaf M., et al.
Publicado: (2016)

Immunotherapy Strategies Against Multiple Myeloma
por: Ma, Jing, et al.
Publicado: (2017)

Is immunotherapy here to stay in multiple myeloma?
por: Rodríguez-Otero, Paula, et al.
Publicado: (2017)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Immunotherapy of Multiple Myeloma: Promise and Challenges
por: Abramson, Hanley N
Publicado: (2021)

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
por: Pavlů, Jiří, et al.
Publicado: (2019)

Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle
por: Malek, Ehsan, et al.
Publicado: (2017)

Hyperhaploid karyotypes in multiple myeloma
por: Sawyer, Jeffrey R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pc1h9sdjpdgj968f52badh4a1n